Legislative History and Legal Framework of EFDA Medical Device Regulation

1. Key takeaways

Medical device regulation in Ethiopia today rests on three layers of legal instruments. The Food and Drug Administration Proclamation No. 1112/2019 is the substantive legal foundation for the regulation of products and establishments, and it has been in force since February 2019. Proclamation No. 1263/2021 establishes the Ethiopian Food and Drug Authority (EFDA). Council of Ministers Regulation No. 531/2023 defines the authority’s organization, powers and duties. Understanding the division of labour among these three documents is the precondition for judging, in any concrete situation, whether a given requirement is a statutory obligation or merely an internal authority requirement. The distinction matters in daily practice: statutory duties cannot be waived or negotiated away, while guidance-level formats, checklists and procedures evolve with each new version of a guideline. Companies that can locate every requirement on the correct layer of this hierarchy argue their positions more effectively during review, respond to inspection findings with greater precision, and avoid the common error of treating an EFDA guideline preference as if it were — or dismissing it because it is not — a binding provision of Proclamation No. 1112/2019.

2. Legal basis

3. Expert insights

Insight 1: the law and the authority were not created at the same time, which explains the dual-track character of the document system. Proclamation No. 1112/2019 first established the regulatory obligations for products and establishments, while EFDA itself was established by Proclamation No. 1263/2021 and its powers were defined by Regulation No. 531/2023. One consequence is that some earlier guidelines still carry the name of the historical authority or remain hosted on historical domains. Companies that search official documents by the new name alone will miss older versions that remain valid and applicable, so document retrieval must cover both naming conventions.

Insight 2: Regulation No. 531/2023 changed the way the regulatory scope is expressed. According to EFDA’s own explanation, before this regulation and Proclamation No. 1112/2019 took effect, the authority regulated products, professionals, premises and practices — the so-called 4P scope. Afterwards, the regulatory scope was narrowed to regulated products and related establishments. This shift means that the regulation of professionals and premises has been partly transferred elsewhere, and when a company judges which categories of establishment must still be licensed by EFDA, it must apply the post-regulation understanding rather than older descriptions of the authority’s mandate.

Insight 3: the legal hierarchy determines what can be flexed and what cannot. The registration and licensing obligations in Proclamation No. 1112/2019 sit at the statutory level and cannot be waived through guidelines; the dossier formats, checklists and procedures set out in EFDA guidelines belong to the implementing level and can be adjusted from version to version. When a company faces a review dispute, invoking a statutory provision carries entirely different persuasive weight from invoking a guideline clause. Knowing which level a contested requirement occupies is therefore a practical advocacy skill, not an academic distinction.

Insight 4: guidelines are revised far more frequently than the law. Take the guideline on non-IVD registration requirements as an example: its first version dates from 2022, and Version 002 was approved on June 15, 2026 and entered into force on June 30, 2026, completing a substantive revision cycle within four years. Tracking the law while ignoring guideline versions is a frequent reason why dossiers are returned: outdated templates, superseded formats and old section references all trigger formal objections that could have been avoided.

Insight 5: historical authority names retain legal significance in documents. Attachments, application forms and templates of some current guidelines still use historical authority identifiers. Companies should submit using the current templates published by EFDA, but when searching historical approvals and older certificates, retrieval must still be conducted under the historical names. Maintaining a mapping between old and new names is a small investment that prevents both submission errors and search failures.

4. Practical recommendations

1. Maintain a version ledger for the three layers of instruments: law, regulation and guideline, each annotated with its effective date.
2. Check the version number and effective date of any guideline before use: do not submit a 2026 application on a first-edition 2022 template.
3. Invoke statutory provisions first in disputes: Proclamation No. 1112/2019 ranks above guidelines.
4. Search official documents under both old and new authority names to avoid missing historically issued but still valid versions.
5. Monitor update announcements in the EFDA publications library: guideline revisions are usually announced with approval and effective dates in advance.
6. Manage statutory obligations and implementing requirements separately: the former is inflexible, the latter negotiable.

5. Verification checklist

• □ Confirmed that the law cited is the current text of Proclamation No. 1112/2019
• □ Confirmed that EFDA’s establishment rests on Proclamation No. 1263/2021 and its powers on Regulation No. 531/2023
• □ Checked the version number and effective date of the guideline to be used
• □ Distinguished statutory obligations from guideline-level requirements
• □ Established a reminder mechanism for version updates of the legal documents

Regulatory information verified as of October 29, 2026. The numbers, dates and division of provisions of the three legal instruments listed above are based on officially published Ethiopian sources; where the names or powers of authorities are adjusted, the information must be re-checked.

• Ethiopia local support: GRZAN assists manufacturers from the Chinese mainland and overseas in dealing with the Ethiopian Food and Drug Authority (EFDA) on marketing authorization (MA), Certificate of Competence (CoC) and import permit applications, including local agent planning and agency agreement review, SRA reliance pathway justification, UMDN coding and classification determination, technical dossier preparation, and the setup of vigilance and post-market surveillance systems.
• Service capabilities: product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), marketing authorization applications and re-registration, low-risk notification eligibility assessment, Essential Principles conformity justification, labelling and instructions-for-use localization in English, and support for vigilance reports and field safety corrective actions.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.